Blueprint Medicines Corporation

BPMC

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 31, 2025

12d

Drug Pipeline

Drug Name	Phase	Indication	Designations
regorafenib	Phase 3	GIST	-
Elenestinib	Phase 3	Indolent Systemic Mastocytosis	-
avapritinib	Phase 2	Solid Tumor, Unspecified, Child	-
BLU-808	Phase 2	Chronic Inducible Urticaria	-
Placebo	Phase 2	Indolent Systemic Mastocytosis	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

BLU-808 Phase 2 Results Expected

Dec 31, 2025BLU-808

Primary completion for BLU-808 trial (NCT06922448) in Allergic Rhinoconjunctivitis

Source

Phase 2

Placebo Phase 2 Results Expected

Dec 31, 2025Placebo

Primary completion for Placebo trial (NCT06922448) in Allergic Rhinoconjunctivitis

Source

Regulatory Approvals

BPMC News

Blueprint Medicines Corporation

BPMC

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 31, 2025

12d

Drug Pipeline

Drug Name	Phase	Indication	Designations
regorafenib	Phase 3	GIST	-
Elenestinib	Phase 3	Indolent Systemic Mastocytosis	-
avapritinib	Phase 2	Solid Tumor, Unspecified, Child	-
BLU-808	Phase 2	Chronic Inducible Urticaria	-
Placebo	Phase 2	Indolent Systemic Mastocytosis	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

BLU-808 Phase 2 Results Expected

Dec 31, 2025BLU-808

Primary completion for BLU-808 trial (NCT06922448) in Allergic Rhinoconjunctivitis

Source

Phase 2

Placebo Phase 2 Results Expected

Dec 31, 2025Placebo

Primary completion for Placebo trial (NCT06922448) in Allergic Rhinoconjunctivitis

Source

Regulatory Approvals

BPMC News